Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates.

ABSTRACT:

Background and objectives

Cardiac rhabdomyoma (CR) is the principal cardiac tumor diagnosed in pediatric age and is commonly associated with tuberous sclerosis complex. In some patients, these masses can cause heart failure and difficult-to-control arrhythmias. There are multiple case reports on use of mammalian target of rapamycin (mTOR) inhibitors, everolimus or sirolimus, in treatment of CRs. We reviewed the current data regarding effectiveness of everolimus and sirolimus in treating of CRs in newborns with hemodynamic repercussions.

Methods

This systematic review was reported according to the PRISMA guidelines. The EBSCO, PubMed, EMBASE, and Lilacs databases were searched for full-text articles reporting the use of everolimus or sirolimus in the treatment of CRs in neona

SUBMITTER: Hurtado-Sierra D 

PROVIDER: S-EPMC12811118 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature